-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Nuvation Bio (NUVB) Undervalued Following Stronger Earnings And A Lower Net Loss?

Simply Wall St·11/15/2026 06:18:03
Listen to the news

Why Nuvation Bio’s Latest Earnings Matter For Investors

Nuvation Bio (NUVB) just reported third quarter and nine month 2026 results, giving investors fresh numbers on how its cancer focused pipeline is translating into revenue and bottom line performance.

The biopharma reported third quarter revenue of US$44.95 million, with a net loss of US$41.9 million and basic loss per share from continuing operations of US$0.12.

Despite the strong headline figures, Nuvation Bio’s share price has come under pressure, with the 30 day share price return down 10.34% and the year to date share price return down 53.50%. The 3 year total shareholder return is up about 19x, pointing to long term holders still sitting on very large gains even as recent momentum has faded around the US$3.99 level.

Spot more biotechs where improving results have not kept pace with recent share price pressure by scanning our hand picked 34 high quality undervalued stocks.

Recent results from Nuvation Bio look stronger, while the share price has been sliding. Does it make more sense to step in around US$3.99 today, or wait for an even cheaper pitch?

Most Popular Narrative: 70% Undervalued

The analyst consensus Narrative on Simply Wall St puts Nuvation Bio’s fair value at $13.11, well above the recent $3.99 close. This frames a wide gap that hinges on how its cancer portfolio plays out over the next few years.

Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.

See why 8 investors see Nuvation Bio as 70% undervalued.

That fair value estimate uses a 7.24% discount rate and builds on analyst forecasts that model revenue growth of 40.28%, a profit margin of 2.27% and a very large future P/E multiple around 577x. The gap between the modeled fair value and the current share price shows how much of the long term glioma and ROS1 lung cancer opportunity the Narrative assumes eventually translates into cash flows.

Analysts are split on how this plays out. The most optimistic see fair value tied to price targets as high as $21, while the most cautious sit closer to $7. The spread itself is a reminder to pressure test any assumptions about trial timing, competitive responses and pricing power.

Result: Fair Value of $13.11 (UNDERVALUED)

Still, Nuvation Bio’s story rests heavily on long dated safusidenib trial outcomes and intense ROS1 competition, either of which could weaken the bullish case.

Find out about the key risks to this Nuvation Bio narrative.

Next Steps

Sentiment around Nuvation Bio is pulled in two directions right now, which is exactly when fresh data can be most useful to you. Do not wait for the consensus to settle before forming an opinion; pressure test the upside assumptions and then weigh them against the 2 key rewards.

Looking for more investment ideas beyond Nuvation Bio?

If Nuvation Bio has sharpened your focus on risk and reward, broaden your watchlist by scanning a few targeted stock ideas that match your style.